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Abstract 
Systematic inflammatory response after spinal cord injury (SCI) is one of the factors leading to lesion de- 
velopment and a profound degree of functional loss. Anti-inflammatory compounds, such as curcumin and 
epigallocatechin gallate (EGCG) are known for their neuroprotective effects. In this study, we investigated 
the effect of combined therapy of curcumin and EGCG in a rat model of acute SCI induced by balloon 
compression. Immediately after SCI, rats received curcumin, EGCG, curcumin + EGCG or saline [daily 
intraperitoneal doses (curcumin, 6 mg/kg; EGCG 17 mg/kg)] and weekly intramuscular doses (curcumin, 
60 mg/kg; EGCG 17 mg/kg)] for 28 days. Rats were evaluated using behavioral tests (the Basso, Beattie, and 
Bresnahan (BBB) open-field locomotor test, flat beam test). Spinal cord tissue was analyzed using histo- 
logical methods (Luxol Blue-cresyl violet staining) and immunohistochemistry (anti-glial fibrillary acidic 
protein, anti-growth associated protein 43). Cytokine levels (interleukin-1β, interleukin-4, interleukin-2, 
interleukin-6, macrophage inflammatory protein 1-alpha, and RANTES) were measured using Luminex 
assay. Quantitative polymerase chain reaction was performed to determine the relative expression of genes 
(Sort1, Fgf2, Irf5, Mrc1, Olig2, Casp3, Gap43, Gfap, Vegf, NfκB, Cntf) related to regenerative processes in in- 
jured spinal cord. We found that all treatments displayed significant behavioral recovery, with no obvious 
synergistic effect after combined therapy of curcumin and ECGC. Curcumin and EGCG alone or in com- 
bination increased axonal sprouting, decreased glial scar formation, and altered the levels of macrophage 
inflammatory protein 1-alpha, interleukin-1β, interleukin-4 and interleukin-6 cytokines. These results 
imply that although the expected synergistic response of this combined therapy was less obvious, aspects of 
tissue regeneration and immune responses in severe SCI were evident. 
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Introduction 
Spinal cord injury (SCI) is one of the most common causes 
of death and paralysis worldwide. The primary insult results 
in neuronal cell death, which is followed by a cascade of 
events. These include the release of excitotoxic glutamate, 
activation of microglia, death of oligodendrocytes and glial 
scar formation (Dubendorf, 1999; Witiw and Fehlings, 2015). 
One of the factors leading to worsening of the injury is the 
immune response after the initial insult, resulting in a release 
of pro-inflammatory cytokines, which trigger the secondary 
processes. Influencing the early immune response after SCI 
may decelerate the cavity formation processes, thus resulting 
in the preservation of spinal tracts and decreased locomotor 
deficits after SCI (Gal et al., 2009; Mietto et al., 2015). 
Curcumin (1,7-bis[4-hydroxy-3-methoxyphenyl]-1,6- 
heptadiene-3,5-dione) is a well-known anti-inflammatory 
agent that is isolated from curcuma longa. It is also known 
for its neuroprotective features and has been studied as an 
effective therapeutic agent in experimental models of SCI 
(Ormond et al., 2012; Sanli et al., 2012). Curcumin applica- 
tion after SCI or TBI results in a suppressed inflammatory 
response via the TLR4-MyD88-NFκB dependent pathway, 
which in turn attenuates the microglial activation and neu- 
ronal apoptosis after injury (Zhu et al., 2014; Ni et al., 2015). 
The nuclear factor kappaB (NF-κB) pathway shows a strong 
correlation with tumor necrosis factor-alpha (TNF-α) and 
interleukin-1 (IL-1) levels after injury (Yuan et al., 2015). 
Additionally, the impact of curcumin on the Stat-3 and NF- 
κB pathway strongly influenced nitric oxide (NO) levels and 
the reduction of astrogliosis after SCI (Wang et al., 2014; 
Machova Urdzikova et al., 2015; Gokce et al., 2016; Sanivar- 
apu et al., 2016). Following curcumin application, increased 
behavioral recovery after SCI was observed (Ormond et al., 
2012; Zu et al., 2014; Machova Urdzikova et al., 2015). More- 
over, curcumin displayed a role in decreased neuropathic 
pain via antagonizing TRPV1 channels (Lee et al., 2013). 
Epigallocatechin gallate (EGCG) is an active compound 
from green tea which is also known for its anti-inflamma- 
tory potential and neuroprotective features (Khalatbary 
and Ahmadvand, 2011). In a model of Alzheimer’s disease, 
EGCG can elevate alpha secretase activity and enhance hy- 
drolysis of the TNF-α-converting enzyme, and thus promote 
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the cleavage of α-c terminal fragment of APP (Rezai-Zadech 
et al 2005). The application of EGCG after SCI decreased 
the level of TNF-α and IL-1, major players in inflammatory 
response after SCI, and consecutively also decreased levels 
of inducible nitric oxide synthase, cyclooxygenase-2, and 
myelin peroxidase. The application of EGCG showed an 
anti-apoptotic effect by decreasing the levels of Bax gene 
expression and immunohistochemical positivity on tunnel 
staining, and increasing expression levels of Bcl2, Bdnf and 
Gdnf genes (Khalatbary et al., 2010; Tian et al., 2013). We 
reported that EGCG decreases the nuclear translocation of 
subunit p65 (RelA) of the NF-κB dimer, and therefore 
attenuates the canonical NF-κB pathway (Urdzikova et al., 
2017). In several studies, EGCG administration after neural 
damage led to a reduction of neuropathic pain (Kuang et al., 
2012; Xifro et al., 2015). Furthermore, several studies have 
shown the effect of EGCG on edema, tissue protection, and 
functional recovery after SCI (Khalatbary et al., 2010; Ge et 
al., 2013). Despite that, all the mechanisms of action of these 
compounds are unknown. Curcumin (Aydin et al., 2014; 
Garcia-Nino et al., 2015; Liu et al., 2017) and EGCG (Dudka 
et al., 2005; Meng et al., 2007) are used for their anti-oxida- 
tive, chelating and immunomodulating properties in various 
diseases. In these therapies, TNF-α and IL-1 level reduction 
is one of the key factors in their pro-regenerative features 
after SCI (Khalatbary and Ahmadvand, 2011; Yuan et al., 
2015) and may result in a synergistic effect of curcumin and 
EGCG. So far, a combination of both drugs is used as a com- 
plementary therapy in experimental cancer therapy (Yunos 
et al., 2011; Eom et al., 2015). 
In this study, the effect of the combined therapy of cur- 
cumin with EGCG in a balloon compression model of acute 
SCI in rats was evaluated. White and grey matter tissue spar- 
ing, axonal sprouting, astrogliosis, the expression of genes 
related to regenerative processes, immunomodulation, and 
behavioral recovery after SCI were assessed. 
Materials and Methods 
Animals 
Ten-week-old male Wistar rats (n = 131; AnLab, Prague, 
Czech Republic), weighing 300 ±15 g, were used in this 
study. The animals were housed in pairs in individually ven- 
tilated cage systems (Techniplast), with food and water ad 
libidum. Animals were separated prior to the injury into the 
two major groups: a behavioral group and a cytokine group. 
Immediately after SCI, all animals from the behavioral group 
were randomly divided into four subgroups for behavioral 
examinations: saline (n = 10), curcumin (n = 13), EGCG 
(n= 19) and curcumin + EGCG (n = 9). These animals were 
also used for histological, immunohistochemical (n = 5/ 
group) and qPCR analysis after behavioral examinations (n 
= 4/group). Animals in the cytokine group consisted of 20 
rats per subgroup (saline, curcumin, EGCG, and curcumin 
+ EGCG), which were sacrificed at different time points (n 
= 5/group per time point: 1, 3, 7 and 10 days) after injury 
and were evaluated for the levels of selected cytokines. All 
experiments were performed in accordance with the Euro- 
pean Communities Council Directive of 22 September 2010 
(2010/63/EU) regarding the use of animals in research, and 
were approved by the Ethics Committee of the Institute of 
Experimental Medicine, Academy of Sciences of the Czech 
Republic (approval number: 277/2011 and 53/2014). 
SCI induction and treatment 
A lesion was created via a balloon-induced spinal cord 
compression as previously detailed (Vanicky et al., 2001; 
Urdzikova et al., 2006). This model was chosen for its rel- 
evance to closed injuries, with vertebrate body and arch 
preserved, leading to a higher validity of local immune re- 
sponse after SCI. Briefly, approximately one centimeter of a 
2-French Fogarty catheter (Edwards, Irvine, CA, USA) was 
inserted into the epidural space through a laminectomy at 
T10, aligned with the midline of the spinal cord and inflated 
for 5 minutes. The volume of the inflated balloon was ad- 
justed to 15 μL and the function was carefully checked in 
every animal. Immediately after SCI, rats received daily (for 
28 days after SCI) intraperitoneal doses of curcumin (Sig- 
ma-Aldrich, St. Louis, MO, USA; 6 mg/kg, diluted in olive 
oil), EGCG (Sigma-Aldrich, 17 mg/kg, diluted in PBS), or 
their combination, and weekly intramuscular injection (1,   
7, 14, 21 and  28  days post-SCI, surrounding lesion area) 
of curcumin (60 mg/kg in olive oil (Ormond et al. 2014), 
Sigma), EGCG (17 mg/kg, diluted in PBS (Tian et al., 2013; 
Renno et al., 2015), or a combination of both drugs. 
Behavioral test 
The Basso, Beattie, and Bresnahan (BBB) open-field 
locomotor test 
Basic locomotor function was evaluated using the BBB open- 
field locomotor test (Basso et al., 1995). Rats were placed in 
an open field area for approximately four minutes every week 
starting seven days after SCI. Animals were scored by two 
independent examiners according to the BBB scale (0–21). 
The scale 0–4 points reflect no or only small movement of 
hindlimbs with no weight support; scale 5–8 points indicate 
larger extent of movement with no weight support; scale 9–14 
points suggest increasing frequency of weight-supported steps 
and hindlimb coordination; scale 15–18 points reflect precise 
movements such as specific paw placement rotation; scale 18– 
20 points indicate tail balance and trunk stability; and scale 21 
points indicate healthy animals. Hindlimbs scored separately, 
and then an average value per animal was calculated. 
Flat beam test 
To evaluate advanced locomotor skills of injured animals, 
such as weight support and hindlimb coordination, the flat 
beam test was used (Goldstein, 1997). The latency (in sec- 
onds) and trajectory of animals crossing the beam was re- 
corded and evaluated. Additionally, the rats were scored ac- 
cording to the modified version of the Goldstein scale (0–7) 
(Goldstein, 1997). The flat beam test measures the ability to 
balance on the beam (scale points 0–2), attempts of cross- 
ing the beam (scale points 2–3) and the frequency of using 
hindlimbs for the task, technique of hindlimb coordination 
and the gait (scale points 4–7). Time score reflects the time 
that each rat needs to start performing the task (maximum   
is 60 seconds). After a pre-training session, animals were 
assessed twice a day for 3 consecutive days, and weekly from 
the third week after injury. 
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Plantar test 
To evaluate the presence of hyperalgesia to thermal noci- 
ceptive stimulus, an Ugo Basile test apparatus (Ugo Basile, 
Comercio, Italy) was used as previously described (Carstens 
and Ansley, 1993). A radiant thermal stimulus was applied 
to the plantar surface of the paws, and the latency (seconds) 
of the paw withdrawal response was measured. 
Tissue processing, histology and immunohistochemistry 
To analyze the effect of curcumin, EGCG, or the combined 
therapy on injured spinal cords, fifteen cross-sections (5 μm 
thickness) per animal were selected at 1-mm intervals along 
the cranio-caudal axis, including the lesion center. Cresyl 
violet-Luxol fast blue staining was used to distinguish the 
white and grey matter (WM/GM) of the injured spinal cord. 
The total volume and distribution of spared white matter/ 
grey matter and cavity size were analyzed using ImageJ 
software (NIH, Bethesda, MD, USA) (Additional Figure 
1A, data are expressed as a percentage to the saline group 
(100%)). For immunohistochemical analysis of axonal 
sprouting, the antibody against Gap43 (Millipore, Billerica, 
MA; 1:2000, overnight 4°C) was used. To visualize primary 
antibody reactivity, goat anti-mouse IgG conjugated with 
Alexa-Fluor 488 (Molecular Probes, Eugene, OR, USA; 1:200, 
2 hours 4°C) was applied. The number of Gap43-positive 
fibers per slide was counted using Tissue FAXS software 
(Tissue Gnostics, Vienna, Austria) across the whole area 
of the section (Additional Figure 1B). The results are dis- 
played as the average number of GAP43-positive fibers per 
slide in percentage, when compared to the saline group 
(set to 100%). To determine the effect of treatment on gli-  
al scar formation, antibody against glial fibrillary acidic 
protein (GFAP) (mouse anti-GFAP-Cy3; Sigma, St. Louis, 
MO, USA; 1:300, overnight 4°C) was used. The thickness of 
GFAP+ glial scar (the square area of GFAP-positive signal 
of high density, directly surrounding the main lesion cavity; 
data are expressed as a percentage per total section area) and 
the number of protoplasmic astrocytes were analyzed using 
ImageJ software (Additional Figure 1C). Histological and 
immunohistochemical images were analyzed and quantified 
using Aioskop 2 plus microscope (Zeiss, Oberkochen, Ger- 
many), LEICACTR6500 microscope (Leica Microsystems, 
Milton Keynes, UK) and TissueFAXS and ImageJ software. 
Quantitative reverse transcription-PCR (qRT-PCR) 
To study the relative expression of rat genes related to re- 
generative processes after SCI, qRT-PCR was applied (Heid 
et al., 1996). 
RNA was isolated from parafomadehyde-fixed spinal cord 
tissue sections using High Pure RNA Paraffin Kit (Roche, 
Penzberg, Germany) (Bibikova et al., 2004; Streubel et al., 
2005). To quantify the amount of RNA, a spectrophotometer 
(NanoPhotometerTM P-Class, Munchen, Germany) was used. 
The isolated RNA was then reverse transcribed into cDNA, 
using Transcriptor Universal cDNA Master (Roche, Penzberg, 
Germany), and a thermal cycler [T100™ Thermal Cycler (Bio- 
Rad, Hercules, CA, USA)]. cDNA solution, FastStart Univer- 
sal Probe Master (Roche, Penzberg, Germany) and TaqMan® 
Gene Expression Assays genes (Gapdh/Rn01775763_g1 
(housekeeping gene), Sort1 (Nt3) /Rn01521847_m1, Olig2/ 
Rn01767116_m1, Fgf2/Rn00570809_m1, Gfap/Rn00566603_ 
m1, Gap43/Rn01474579_m1, Vegf/Rn01511601_m1, Casp3/ 
Rn00563902_m1, Cntf/Rn00755092_m1,Irf5/Rn01500522_ 
m1, Mrc1/Rn01487342_m1, and Life Technologies, Carlsbad, 
CA, USA) were used to perform PCR. 
The final volume of 10 μL, containing 25 ng of extracted 
RNA was amplified by a real-time PCR cycler (StepOne- 
Plus™, Life Technologies, Carlsbad, CA, USA). All am- 
plifications were run under the same cycling conditions (2 
minutes at 50°C, 10 minutes at 95°C, followed by 40 cycles 
of 15 seconds at 95°C and 1 minute at 60°C). A negative 
control was included in each array. Tested samples were run 
in duplicates, and to determine the relative quantification   
of gene expression, the ∆∆Ct method was applied (Pfaffl, 
2001). Data were analyzed by StepOnePlus® software (Life 
Technologies, Carlsbad, CA, USA). The gene expression lev- 
els were normalized using Gapdh as a reference gene, and all 
data are related to the values of SCI rats treated with vehicle. 
A log2 scale was used to display the symmetric magnitude 
for up and down regulated genes. 
Luminex assay 
In order to evaluate the effect of anti-inflammatory drugs 
(curcumin, EGCG and combined therapy) on levels of cy- 
tokines after SCI, Luminex assay was applied (Urdzikova  
et al., 2014). On the 1st, 3rd, 7th and 10th days after SCI, the 
samples of injured spinal cord were taken, and incubated in 
cell culture media (24 hours, DMEM (Sigma), supplemented 
with 10% fetal bovine serum and 0.2% primocin). The levels 
of cytokines (six-plexbead assay for interleukin-1β (IL-1β), 
interleukin-4 (IL-4), interleukin-2 (IL-2), interleukin-6 (IL- 
6), macrophage inflammatory protein 1-alpha (MIP-1α), 
and regulated on activation, normal T cell expressed and 
secreted (RANTES); Millipore, Billerica, MA, USA) in the 
media were detected using a customized Milliplex inflam- 
matory cytokine kit and Magpix instrumentation software. 
The raw data, consisting of mean fluorescence intensity, us- 
ing a five-parameter logistic fit curve (standard curve) were 
recalculated to the concentration of each cytokine (ng/μL). 
Results are displayed as a percentage change from non-le- 
sioned tissue (100%) for each time point. 
Statistical analysis 
Statistical evaluation was performed by SigmaStat software 
(Sistat Software Inc., San Jose, CA, USA). To evaluate the 
differences between treatment groups in behavioral study, 
white/grey matter sparing, and glial scar formation, two- 
way repeated measures analysis of variance (ANOVA) was 
used. For the evaluation of qPCR and luminex results, two- 
way ANOVA was applied. Axonal sprouting was evaluated 
by one-way ANOVA. As a pair-to-pair post-hoc test, the Stu- 
dent-Newman-Keuls (SNK) test was chosen. Data in graphs 
are represented as the mean ± SEM. Differences were consid- 
ered statistically significant when P < 0.05. F values (ANOVA) 
or q values (SNK test) are presented when P < 0.05. 
Results 
Behavioral recovery 
BBB open-field locomotor test 
Behavioral recovery after SCI was assessed by the BBB open- 
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field locomotor test. Results showed that behavioral recovery 
of rats treated with saline only reached a plateau four weeks 
after injury, with an average BBB score less than 6. Applica- 
tion of EGCG showed only mild improvement in locomotor 
recovery observed in the BBB open-field locomotor test. 
However, both curcumin and curcumin + EGCG treated 
animals showed significantly higher recovery in comparison 
with saline treated animals (Figure 1A) (two-way repeated 
measures ANOVA F = 4.039, P < 0.05; SNK test: curcumin 
vs. saline, q = 4.252, P < 0.05; curcumin + EGCG vs. saline, 
q = 3.509, P < 0.05). Furthermore, the combined therapy  
did not achieve a higher score than with application of cur- 
cumin only (SNK test: curcumin vs. saline: 1 week, q = 4.74, 
P < 0.01; 2 weeks, q = 3.744, P < 0.05; 3 weeks, q= 4.549, P 
< 0.05; 4 weeks, q = 3.789, P < 0.05; 5 weeks, q = 3.760, P < 
0.05; 7 weeks, q = 4.147, P < 0.05; 9 weeks, q = 3.836, P < 0.05; 
curcumin vs. EGCG: 2 weeks, q = 4.172, P < 0.05; 3 weeks, 
q = 3.814, P < 0.05; 4 weeks, q = 3.682, P < 0.05; EGCG + 
curcumin vs. saline: 3 weeks, q = 3.592, P < 0.05; 4 weeks, q 
= 3.837, P < 0.05; 5 weeks, q = 3.900, P < 0.05; 7 weeks, q = 
3.699, P < 0.05; 9 weeks, q = 3.906, P < 0.05; EGCG + cur- 
cumin vs. EGCG: 4 weeks, q = 3.694, P < 0.05). 
Flat beam test 
Advanced locomotor skills after SCI were evaluated by the 
flat beam test. In this more physically demanding test, sa- 
line treated animals reached an average value of 1, which 
represents the ability to balance on the beam for at least 30 
seconds consecutively without being able to cross it. All treat- 
ed groups reached values above two, which represents the 
ability to cross at least half of the measured distance. Animals 
treated with EGCG showed a significantly higher locomotor 
score than saline treated animals (SNK test: EGCG vs. saline, 
q = 3.594, P < 0.05). In the beginning, the combined curcum- 
in and EGCG group showed higher scores than curcumin or 
EGCG treated and saline treated animals. However, both 
groups containing curcumin showed only a trend toward the 
significance when compared to saline treated animals (SNK 
test: curcumin vs. saline: q = 2.529, P = 0.08; curcumin + 
EGCG vs. saline: q = 3.361, P = 0.096) (Figure 1B). 
Simultaneously, the latency of flat beam crossing was mea- 
sured (flat beam time score). The lowest latency in crossing 
the beam was observed in the EGCG group (SNK test: saline 
vs. EGCG: q = 4.343, P < 0.05; curcumin vs. EGCG, q = 3.828, 
P < 0.05). The latency in crossing the beam in the curcumin + 
EGCG group was lower than that in the EGCG group, how- 
ever, there was no synergistic effect of the combined therapy 
(Figure 1C) (SNK test: EGCG vs. saline: 7 weeks, q = 4.364, 
P < 0.01; 8 weeks, q = 4.352, P < 0.05; 9 weeks, q = 3.874, P < 
0.05; curcumin vs. saline, 7 weeks, q = 2.922, P < 0.05; EGCG 
+ curcumin vs. saline, 7 weeks, q = 3.679, P < 0.05). 
Plantar test 
To estimate the effect of curcumin, EGCG and their com- 
bination on latency of response to nociceptive thermal 
stimulus, a plantar test apparatus was used. No increased 
hyperalgesia in response to nociceptive thermal stimulus 
was observed in any of the treated animals (SNK test: saline 
vs. curcumin, 1 week, q = 4.74, P < 0.05; 9 weeks, q = 4.088, 
P < 0.05; EGCG vs. curcumin, 1 week, q = 2.983, P < 0.05; 
EGCG + curcumin vs. curcumin, 1 week, q = 3.685, P < 0.05, 
9 weeks, q = 4.282, P < 0.05; EGCG + curcumin vs. EGCG, 2 
weeks, q = 4.345, P < 0.05) (Figure 1D). 
Histology and immunohistochemistry 
White and grey matter 
The effect of the combined therapy of curcumin and EGCG 
on the preservation of spinal cord white (Figure 2A) and grey 
matter (Figure 2B) was evaluated on a series of transverse 
sections two months after SCI. None of the applied treat- 
ments showed a statistically significant effect on the preserva- 
tion of injured spinal cord white and grey matter. Volume per 
15 mm long analyzed spinal cord tissue was 23.1, 26.18, 25.98, 
and 21.4 mm3 in the saline, EGCG, curcumin, and curcumin 
+ EGCG groups, respectively (Figure 2G). Either curcumin 
or EGCG application led to minor preservation of spinal cord 
tissue after SCI. However, their combination had no positive 
effect on tissue sparing (Figure 2A, B, G). On the contrary, 
the combined therapy of curcumin and EGCG showed a 
strong trend toward decreasing cavity size when compared to 
the control saline treated animals (Figure 2F) (SNK test: gray 
matter: EGCG vs. EGCG + curcumin, 3 cranial, q = 4.013, P 
< 0.05; 2 cranial, q = 6.461, P < 0.001; 1 cranial, q = 4.865, P < 
0.01; EGCG vs. saline, 2 cranial, q = 3.679, P < 0.05; 1 cranial, 
q = 3.221, P < 0.05; EGCG vs. curcumin, 2 cranial, q = 2.967, 
P < 0.05; 1 cranial, q = 4.556, P < 0.05; white matter: saline vs. 
EGCG + curcumin, 2 cranial, q = 3.454, P < 0.05; EGCG vs. 
EGCG + curcumin, 1 cranial, q = 4.302, P < 0.05; 2 cranial, q 
= 5.372, P < 0.01; curcumin vs. EGCG + curcumin, 2 cranial, 
q = 3.753, P < 0.05). 
Astrogliosis 
To detect the effect of the combined therapy of curcumin 
and EGCG on glial scar formation, the area of GFAP+ scar 
tissue (in%) on a series of transversal spinal cord sections 
was measured two months after SCI. None of the single 
treatment significantly reduced astrogliosis, however, the 
number of protoplasmic astrocytes was reduced in both 
curcumin and EGCG treated animals (Figure 2C, D). Com- 
bined therapy showed a partial decrease of GFAP+ scar 
tissue area in the central region of the damaged spinal cord, 
when compared to the saline group (two-way ANOVA; SNK 
test: 1 caudal, P < 0.05, 2 caudal, P < 0.001). The number of 
protoplasmic astrocytes was not changed in the curcumin 
+ EGCG group (SNK test: glial scar: saline vs. curcumin,    
2 caudal, q = 4.746, P < 0.01; saline vs. EGCG: 2 caudal, q 
= 2.967, P < 0.05; saline vs. EGCG + curcumin, 1 caudal, q 
= 4.206, P < 0.05, 2 caudal, q = 3.352, P < 0.05; EGCG vs. 
curcumin, 2 caudal, q = 7.139, P < 0.001; EGCG vs. EGCG 
+ curcumin, 2 caudal, q = 5.881, P < 0.001) (SNK test: saline 
vs. curcumin, central, q = 4.230, P < 0.05, 1 caudal, q = 3.949, 
P < 0.05; EGCG + curcumin vs. saline, 2 caudal, q = 3.867, P 
< 0.05) (Figure 2C, D). 
Axonal sprouting 
The number of sprouting axons was measured using GAP43+ 
staining on a series of transversal spinal cord sections, two 
months after injury. Both curcumin and EGCG compounds 
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Figure 1 Locomotor and sensory recovery in rats following curcumin and epigallocatechin gallate (EGCG) application after spinal cord injury. 
(A–C) The effect of curcumin, EGCG, and their combination on locomotor recovery after spinal cord injury was evaluated using the Basso, Beattie, 
and Bresnahan (BBB) open-field locomotor test (A), flat beam test (B), and flat beam time score (C). Animals treated with combined therapy of 
curcumin and EGCG, or curcumin alone, performed significantly better in the BBB open-field locomotor test than animals treated with saline. In 
the flat beam test, EGCG treated animals showed the best recovery, followed by curcumin + EGCG treated animals. (D) The thermal nociception 
was evaluated using the plantar test. No additional hyperalgesia was found after application of any of the used drugs. Two-way repeated measures 
analysis of variance with the Student-Newman-Keuls post hoc test was used to determine statistical significance. *P < 0.05 (The color of asterisks 
indicates the statistically different group(s)). 
 
Figure 2 Histological and immunohistochemical 
analysis results of injured spinal cords. 
The amount of spared white (A) and grey matter 
(B) was determined 9 weeks after spinal cord injury 
(SCI) in rats treated with saline, curcumin, EGCG, 
or their combination. No statistically significant ef- 
fect of applied drugs on tissue preservation was ob- 
served. In addition, the volume of white matter and 
gray matter across the measured regions revealed 
no significant difference (G). However, a strong 
trend toward smaller cavity size was found (F). 
The effect of the application of curcumin, EGCG, 
or their combination on glial scar formation (C), 
and the average number of protoplasmic astrocytes 
per section (D) around the central lesion cavity 
was measured 9 weeks after SCI. The combined 
application of curcumin and EGCG had a suppres- 
sive effect on glial scar formation at the area of the 
lesion epicenter. In the central region of the injury, 
all treatments showed a positive effect on decreas- 
ing the number of protoplasmic astrocytes. The 
distribution of the effect on X axis is measured as 
distance in mm from the lesion center (set as 0) (A– 
D). The effect of applied curcumin, EGCG, or their 
combination on axonal sprouting. (E) The combi- 
nation of curcumin and EGCG had a synergistic 
effect on axonal sprouting, when compared to 
saline treated animals. Two-way repeated measures 
analysis of variance (ANOVA) with Student-New- 
man-Keuls test was used to determine statistical 
significance (A–D). One-way ANOVA with Stu- 
dent-Newman-Keuls test was used to  determine 
the level of statistical significance (E–G). *P < 0.05 
(the color of asterisk indicates the statistically dif- 
ferent group(s)). Symbol of # is used when trend 
toward significance has reached statistical value P 
= 0.05–0.06. n = 5 per group. 
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increased the number of GAP43+ fibers compared to saline 
treated animals. This effect was enhanced in the combined 
therapy, however, remained only as a strong trend toward 
significance (Figure 2E) (one-way ANOVA: F = 2.723, P = 
0.087; SNK test: q = 3.978, P = 0.057). 
Endogenous gene response 
The relative gene expression of several factors (Sort1, Fgf2, 
Irf5, Mrc1, Olig2, Casp3, Gap43, Gfap, Vegf, NfκB, Cntf) 
related to regenerative processes was measured from in- 
jured spinal cord tissue two months after injury. Both cur- 
cumin and EGCG showed a similar pattern in expression   
of targeted genes. The expression of most of the genes was 
upregulated or unchanged in comparison with saline treat- 
ed animals, with only Gfap downregulated. The combined 
therapy showed opposite effects than each single treatment 
in all targeted genes, except for Olig2 and Gfap. This pattern 
was statistically significant in most cases when compared 
with each single treatment (SNK test: EGCG + curcumin vs. 
curcumin, Sort 1: q = 5.151, P < 0.01, FGF2 q = 4.1, P < 0.05, 
Irf5: q = 3.71, P < 0.05; Mrc1: q = 4.238, P < 0.05; Casp3: q = 
6.373, P < 0.01; Gap43: q = 4.965, P < 0.01; Cntf: q = 5.664, P 
< 0.01; EGCG + curcumin vs. EGCG, Irf5: q = 5.386, P < 0.01; 
Casp3: q = 4.023, P < 0.05; NFκB: q = 4.212, P < 0.05; Cntf: q 
= 4.085, P < 0.05; saline vs. EGCG, Irf5: q = 4.059, P < 0.05; 
saline vs. curcumin, Casp3, q = 4.160, P < 0.05) (Figure 3). 
Inflammatory response 
Changes in levels of cytokines (IL-1β, IL-4, IL-2, IL-6, MIP- 
1α, and RANTES,) after SCI were measured. At specific 
time points (1, 3, 7 and 10 days after injury), the effect of 
curcumin, EGCG or their combination was evaluated. In the 
curcumin + EGCG group, MIP-1α level was elevated for the 
first three days compared to that in the saline, curcumin or 
EGCG groups (1 day: two-way ANOVA, SNK test: P < 0.001, 
details at the bottom of the paragraph). No other changes 
were observed during this period. Seven days after injury,  
in the treated animals, we observed decreased levels of IL- 
4, IL-1β and IL-6 (two-way ANOVA, SNK test; curcumin 
vs. curcumin + EGCG, P < 0.05), and the decreased level of 
IL-6 persisted until day ten after injury. In the single treat- 
ment, curcumin initially decreased levels of IL-2 (two-way 
ANOVA, SNK test: curcumin vs. curcumin + EGCG, P < 
0.05), and RANTES (two-way ANOVA, SNK test; curcumin 
+ EGCG vs. curcumin, P < 0.05; saline vs. curcumin, P < 0.05) 
and increased the level of IL-6 (two-way ANOVA, SNK test: 
curcumin vs. curcumin + EGCG, P < 0.05; curcumin vs. 
EGCG, P < 0.05; curcumin vs. saline, P < 0.05; Figure 4). It 
is important to note that there was a surge in MIP-1α level at 
one day after injury in the curcumin + EGCG group, which 
persisted through days three and seven after injury. MIP-1α 
levels in the curcumin + EGCG group were reduced by day 
10 after injury to levels in the curcumin or EGCG groups 
(SNK test: EGCG + curcumin vs. saline, MIP-1α: day 1, q = 
5.615, P < 0.001; RANTES: day 1, q = 3.930, P < 0.05; EGCG 
+ curcumin vs. curcumin, MIP-1α, day 1, q = 7.750, P < 0.001; 
IL-1β, day 1, q = 3.892, P < 0.05; IL-2, day 1, q = 4.505, P < 
0.05; RANTES, day 1, q = 4.756, P < 0.05; EGCG + curcumin 
vs. EGCG, MIP-1α, day 1, q = 6.039, P < 0.001). 
Discussion 
In our study, the combined therapy for the treatment of 
experimental SCI, using two anti-inflammatory compounds 
curcumin and EGCG, had some positive effects on behav- 
ioral recovery, decreased glial scar formation, and supported 
axonal sprouting. No spared white and grey matter was 
observed. In addition, the combined therapy influenced 
inflammatory response via regulating cytokine levels and 
altered the gene expression of regenerative process-related 
markers. The combined therapy did not exhibit synergis-   
tic effects compared to application of curcumin or EGCG 
alone. No studies have been reported on the detailed infor- 
mation regarding the combined therapy of curcumin and  
EGCG for the treatment of experimental SCI. An increasing 
number of publications have been reported on the positive 
effect of curcumin on an experimental model of SCI. An in- 
direct impact of attenuated immune response may decrease 
apoptosis, enhance axonal sprouting or modulate glial scar 
formation, leading to behavioral recovery after SCI (Ormond 
et al., 2012; Zu et al., 2014) or reducing neuropathic pain 
(Lee et al., 2013). Curcumin influenced the regenerative 
processes, in which the most commonly described is the 
immunomodulatory effects, through the Jak/Stat3 and the 
TLR4-MyD88-NFκB pathways (Wang et al., 2014; Machova 
Urdzikova et al., 2015; Gokce et al., 2016). Immunomodula- 
tion by curcumin or EGCG inhibited the Jak/stat signaling 
pathway, leading to reduction of glial scar formation (You et 
al., 2017). The Jak/stat signaling pathway was also influenced 
by the combined therapy of curcumin and EGCG (Figures 
3, 4). Decreased NF-κB activity, along with reduced levels 
of TNF-α and IL-1 and decreased expression of GFAP after 
SCI was also reported after curcumin application (Yuan et 
al., 2015). Application of EGCG after SCI not only promot- 
ed axonal sprouting (GAP-43 staining), but also increased 
GFAP immunoreactivity (Renno et al., 2014; Renno et al., 
2015). In this study, we observed in vivo a trend towards an 
increase in GAP-43 levels after combined therapy of cur- 
cumin and EGCG (Figure 2E). In our in vitro studies, we 
tested the growth of neurites from adult dorsal root ganglia 
(DRGs) in the presence of EGCG. We did not observe any 
growth facilitation. However, EGCG reduced neuronal death 
after application of H2O2 in hippocampal neuronal culture, 
indicating a neuroprotective and anti-oxidative effect (data 
not shown/unpublished data). The concentrations of EGCG 
used in SCI studies vary from 10 to 50 mg/kg (Tian et al., 
2013; Renno et al., 2015; Urdzikova et al., 2017). In our pre- 
vious study, we used a concentration within the lower range 
to prevent a possible cytotoxic effect resulting from a high 
concentration of EGCG, since it was reported that a high 
concentration of EGCG (> 10 μM) can lead to increased 
apoptosis and mitochondrial dysfunction in hippocampal 
culture in vitro (Yin et al., 2009). Similarly to EGCG, cur- 
cumin can affect cell proliferation and survival and neurite 
outgrowth in a dose dependent manner. Curcumin at high 
concentration (above 10 μM) inhibited the proliferation and 
survival of various types of cancer cells (Yang et al., 2017). 
In PC12 cells, however, the in vitro application of curcum- 
inoids at concentrations from 100 nM up to 20 μM has led 
to a significant increase of neurite outgrowth through stim- 
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ulating MAPK/ERK and PKC dependent pathways (Liao  
et al., 2012; Dikmen, 2017). In addition, curcumin can act 
through the Akt/GSK-3β dependent pathway and regulate 
brain-derived neurotrophic factor level (Hoppe et al., 2013). 
Curcumin also has a dose dependent effect on the neural 
stem cells isolated from the subventricular zone of adult rats. 
Curcumin at 500 nM supported neurosphere proliferation, 
but at a higher concentration (μM), it resulted in widespread 
apoptosis (Ormond et al., 2014). In this study, we also ob- 
served downregulated Gfap expression and decreased GFAP 
staining intensity (Figures 2C and 3). However, the neuro- 
protective and antiapoptotic roles of curcumin and EGCG 
lead to partial tissue sparing after SCI, which were not ob- 
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Figure 3 Gene expression changes in injured spinal cords after 
application of curcumin, epigallocatechin gallate (EGCG) or their 
combination. 
Relative gene expression of factors related to the recovery process in 
response to application of curcumin, EGCG or their combination 9 
weeks after spinal cord injury. The expression level of saline treated 
animals was set as zero value. One-way analysis of variance with Stu- 
dent-Newman-Keuls post hoc test was used to determine the level of 
statistical significance. *P < 0.05(the color of asterisk indicates the sta- 
tistically different group(s)). n = 4 per group. 
served in the combined therapy of curcumin and EGCG. 
One important finding of this study is that the levels of  
the chemokine MIP-1α increased dramatically one day after 
injury, which persisted to days three and seven after injury. 
MIP-1α has been implicated in cell adhesion and migration, 
which might be required in the early phase after injury to 
mobilize stem cells and astrocytes to the site of injury. Fur- 
thermore, recent observations have suggested that MIP-1α  
is not only a chemokine, but also has a pivotal role in the 
growth and survival of many cell types (Maurer and von Ste- 
but, 2004; Terpos et al., 2005). 
Moreover, the anti-oxidative effect of curcumin leads to an 
increased level of super oxide dismutase (Sahin Kavakli et al., 
2011). Additionally, a dose dependent effect of curcumin on 
stem cell proliferation has been reported (Son et al., 2014). It 
is important to note that the combined therapy of curcumin 
and neural stem cells has been successfully used in experi- 
mental SCI, showing that curcumin has the potential to sup- 
port the paracrine effect of stem cells (Ormond et al., 2014). 
EGCG, on the contrary, is studied much less in SCI. Stud- 
ies have demonstrated that EGCG can affect neuropathic 
pain (Xifro et al., 2015), tactile allodynia (Kuang et al., 2012) 
and thermal hyperalgesia (Alvarez-Perez et al., 2015). In ad- 
dition, EGCG has been shown to decrease pro-inflammatory 
molecules, such as RhoA, FASN and TNF-α after SCI (Al- 
varez-Perez et al., 2015). EGCG has caused an improvement 
in locomotor recovery after SCI, which was described due to 
the positive impact on lipid peroxidation, neuronal apopto- 
sis, and overall spinal cord tissue sparing (Khalatbary et al., 
2010; Tian et al., 2013). In this study, only mild improve- 
ment was observed on thermal hyperalgesia after application 
of EGCG and curcumin (Figure 1D). EGCG exhibited an 
anti-edema effect after SCI through downregulating AQP-4 
and GFAP protein levels, suggesting a neuroprotective effect 
 
 
 
5,500 
5,000 
4,500 
4,000 
1,500 
1,000 
500 
0 
B 
 
 
 
 
 
 
 
MIP-1α   IL-4 IL-1β IL-2 IL-6 RANTES 
 
2,200 
2,000 
1,800 
1,600 
1,400 
600 
400 
200 
0 
 
 
 
 
 
 
 
 
 
 
 
 
 
MIP-1α   IL-4 IL-1β IL-2 IL-6 RANTES 
Figure 4 Effect of curcumin, 
EGCG, or their combination 
on cytokine levels in injured 
spinal cords. 
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(Ge et al., 2013). Functional recovery after EGCG applica- 
tion could be attributed to the upregulation of GAP-43 pro- 
tein level (Renno et al., 2015), and increased intrinsic levels 
of BDNF and GDNF (Tian et al., 2013) after SCI. 
Some of these effects that were observed in the combined 
therapy of curcumin and EGCG contributed to the recovery 
of SCI. The behavioral recovery in the combined therapy   
of curcumin and EGCG was similar to application of cur- 
cumin alone; however, no synergistic effect was evident. In 
more advanced tests, such as the flat beam test, the scores 
were closer to the EGCG results. According to the publica- 
tions (Khalatbary et al., 2010; Renno et al., 2014), the EGCG 
therapy was more sensitive in mild to moderate injuries 
affecting advanced locomotor settings. The advanced setting 
of the flat beam test shows the ability of focusing on the 
task and balancing without proper usage of the hindlimbs. 
To be able to perform such a task, the animals must score 
from 8 to 10 in the BBB open-field locomotor test. A score 
of 1 indicates that to be able to balance on the flat, animals 
must use forelimbs for movement. To reach scores higher 
than 3, animals must be able to support their weight (above 
score 10 in the BBB open-field locomotor test) and at least 
partially coordinate hindlimb movements (scores 11-14 in 
the open-field locomotor test). However, the ability to cross 
the beam (score 3) does not directly correlate with the BBB 
open-field locomotor test score. Animals able to hold the 
beam with their hindlimbs from the sides can reach the tar- 
get zone, even though in the BBB open-field locomotor test 
they would not perform better than animals trying to step  
on the top of the beam. Therefore, the flat beam test also re- 
flects the motivation of the animal to reach the target zone, 
even without stepping properly. The sensory function and 
thermal hyperalgesia of the rats were assessed by the plantar 
test, which measures withdrawal latency of the hindlimbs to 
the thermal stimulus. The combined therapy of curcumin 
and EGCG did not negatively affect thermal allodynia. To 
report more about the effect of treatment on allodynia, stud- 
ies on mechanical stimulus need to be added. The combined 
therapy of curcumin and EGCG does affect the immune 
response in a more discrete manner than monotherapy. We 
observed decreased levels of IL-1β and IL-6, which are in 
consistent with described anti-inflammatory properties of 
both compounds (Khalatbary and Ahmadvand, 2011; Wang 
et al., 2014; Gokce et al., 2016). In addition, with the excep- 
tion of the 7th day after SCI, IL-4 levels were above the values 
measured in saline treated animals at other time points. The 
elevated level of MIP-1α in the early phase of SCI may func- 
tion not only as a pro-inflammatory chemokine, but also as 
a molecule to promote migration, growth and survival. 
In conclusion, the combined therapy of curcumin and 
EGCG for treatment of experimental SCI led to behavioral 
recovery, even though not significantly superior to mono- 
therapy. The combined therapy of curcumin and EGCG did 
not influence growth factor response and spinal cord tissue 
sparing, but it displayed a strong immunomodulatory re-  
sponse after SCI, and supported axonal sprouting and glial 
scar reduction. Although the expected synergistic response 
of this combined therapy was not achieved, different aspects 
of tissue regeneration in severe SCI were understood. 
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